Statins and prostate cancer diagnosis and grade in a veterans population

Journal of the National Cancer Institute

Volumn 103, Issue 11, 2011, Pages 885-892

  Farwell, Wildon R ^a,b   D'Avolio, Leonard W ^a   Scranton, Richard E ^b   Lawler, Elizabeth V ^a,b,d   Gaziano, J Michael ^a,b,c  

^a VA BOSTON HEALTHCARE SYSTEM   (United States)

^b Division of Aging   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d BOSTON UNIVERSITY SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FLUINDOSTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOOP DIURETIC AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; PRAVASTATIN; PROSTATE SPECIFIC ANTIGEN; SIMVASTATIN; THIAZIDE DIURETIC AGENT;

AGED; ARTICLE; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER GRADING; CANCER INCIDENCE; CANCER PREVENTION; CANCER RISK; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIABETES MELLITUS; DRUG USE; FOLLOW UP; GLEASON SCORE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; RETROSPECTIVE STUDY; VETERAN;

EID: 79958848145     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djr108     Document Type: Article

References (24)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;60(5):277-300.
2. Platz EA, Leitzmann MF, Visvanathan K, et al. Statin drugs and risk of advanced prostate cancer. J Natl Cancer Inst. 2006;98(24):1018-1025.
3. Jacobs EJ, Rodriguez C, Bain EB, Wang Y, Thun MJ, Calle EE. Cholesterol-lowering drugs and advanced prostate cancer incidence in a large U.S. cohort. Cancer Epidemiol Biomarkers Prev. 2007;16(11):2213-2217. (Pubitemid 351196351)
4. Flick ED, Habel LA, Chan KA, et al. Statin use and risk of prostate cancer in the California Men's Health Study Cohort. Cancer Epidemiol Biomarkers Prev. 2007;16(11):2218-2225. (Pubitemid 351196352)
5. Murtola TJ, Tammela TLJ, Lahtela J, Auvinen A. Cholesterol-lowering drugs and prostate cancer risk: a population-based case-control study. Cancer Epidemiol Biomarkers Prev. 2007;16(11):2226-2232. (Pubitemid 351196353)
6. Boudreau DM, Yu O, Buist DSM, Miglioretti DL. Statin use and prostate cancer risk in a large population-based setting. Cancer Causes Control. 2008;19(7):767-774.
7. Majumdar SR, McAlister FA, Eurich DT, Padwal RS, Marrie TJ. Statins and outcomes in patients admitted to hospital with community acquired pneumonia: population based prospective cohort study. BMJ. 2006;333(7576):999.
8. Brookhart MA, Patrick AR, Dormuth C, et al. Adherence to lipid-lowering therapy and the use of preventive health services: an investigation of the healthy user effect. Am J Epidemiol. 2007;166(3):348-354. (Pubitemid 47216808)
9. Murtola TJ, Tammela TLJ, Maattanen L, et al. Prostate cancer and PSA among statin users in the Finnish prostate cancer screening trial. Int J Cancer. 2010;127(7):1650-1659.
10. Platz EA, Till C, Goodman PJ, et al. Men with low serum cholesterol have a lower risk of high-grade prostate cancer in the placebo arm of the prostate cancer prevention trial. Cancer Epidemiol Biomarkers Prev. 2009;18(11):2807- 2813.
11. D'Avolio LD, Farwell WR, Nguyen TM, et al. Evaluation of a generalizable approach to clinical information retrieval using the Automated Retrieval Console (ARC). J Am Med Inform Assoc. 2010;17(4):375-382.
12. Scranton RE, Young M, Lawler E, Solomon D, Gagnon D, Gaziano JM. Statin use and fracture risk. Arch Intern Med. 2005;165(17):2007-2012.
13. Farwell WR, Scranton RE, Lawler EV, et al. The association between statins and cancer incidence in a veterans population. J Natl Cancer Inst. 2008;100(2):134-139. (Pubitemid 351480564)
14. ClinicalTrials.gov. Identifier NCT00572468. 2007. http://clinicaltrials. gov/ct2/show/NCT00572468?term=statin+prostate+cancer&rank=1. Accessed February 1, 2011.
15. Mondul AM, Selvin E, DeMarzo AM, Freedland SJ, Platz EA. Statin drugs, serum cholesterol, and prostate-specific antigen in the National Health and Nutrition Examination Survey 2001-2004. Cancer Causes Control. 2010;21(10):1575-1583.
16. Mener DJ, Cambio A, Stoddard DG, Martin BA, Palapattu GS. The impact of HMG-CoA reductase therapy on serum PSA. Prostate. 2010;70(6):608-615.
17. Freeman MR, Solomon KR. Cholesterol and prostate cancer. J Cell Biochem. 2004;91(1):54-69.
18. Williams TM, Hassan GS, Li J, et al. Caveolin-1 promotes tumor progression in an autochthonous mouse model of prostate cancer. J Biol Chem. 2005;280(26):25134-25145.
19. Chao WT, Fan SS, Chen JK, Yang VC. Visualizing caveolin-1 and HDL in cholesterol-loaded aortic endothelial cells. J Lipid Res. 2003;44(6):1094-1099. (Pubitemid 37279627)
20. Li YC, Park MJ, Ye SK, Kim CW, Kim YN. Elevated levels of cholesterol-rich lipid rafts in cancer cells are correlated with apoptosis sensitivity induced by cholesterol-depleting agents. Am J Pathol. 2006;168(4):1107-1118.
21. Mondul AM, Clipp SL, Hezlsouer KJ, Platz EA. Association between plasma total cholesterol concentration and incident prostate cancer in the CLUE II cohort. Cancer Causes and Control. 2010;21(1):61-68.
22. Liu CF, Chapko M, Bryson CL, et al. Use of outpatient care in Veterans Health Administration and Medicare among veterans receiving primary care in community-based and hospital outpatient clinics. Health Serv Res. 2010;45(5, pt 1):1268-1286.
23. Ronquist G, Rodriguez LAG, Ruigomez A, et al. Association between captopril, other antihypertensive drugs and risk of prostate cancer. Prostate. 2004;58(1):50-56. (Pubitemid 38057988)
24. Perron L, Bairati I, Harel F, Meyer F. Antihypertensive drug use and the risk of prostate cancer. Cancer Causes Control. 2004;15(6):535-541. (Pubitemid 39070071)